Drug Type Small molecule drug, Liposomal Drug |
Synonyms Lipotecan, TLC 388, TLC-388 + [2] |
Target |
Action inhibitors |
Mechanism HIF-1α inhibitors(Hypoxia-inducible factor 1 alpha inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationSpecial Review Project (China) |
Molecular FormulaC39H30N8O15 |
InChIKeyJCCCLGDYMMTBPM-HXDHBHDHSA-N |
CAS Registry1432468-79-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Portal Vein Thrombosis | Phase 2 | Taiwan Province | 14 Apr 2017 | |
Venous Thrombosis | Phase 2 | China | - | 14 Apr 2017 |
Rectal Cancer | Phase 2 | Taiwan Province | 26 Dec 2015 | |
Neuroendocrine Tumors | Phase 2 | Taiwan Province | 10 Jun 2015 | |
Hepatocellular Carcinoma | Phase 2 | China | 12 Nov 2014 | |
Hepatocellular Carcinoma | Phase 2 | China | 12 Nov 2014 | |
Advanced Hepatocellular Carcinoma | Phase 2 | China | 10 Apr 2014 | |
Advanced Hepatocellular Carcinoma | Phase 2 | Taiwan Province | 10 Apr 2014 | |
Advanced Renal Cell Carcinoma | Phase 2 | Taiwan Province | 30 Nov 2012 | |
Metastatic Renal Cell Carcinoma | Phase 2 | Taiwan Province | 30 Nov 2012 |
Phase 2 | 23 | htynvkwuaw(jhfgduwluc) = olgvtiwzoc ibcikkqrlv (epxnefxuks, 0.4 - 15) View more | Negative | 01 May 2020 | |||
Not Applicable | - | gmhvdnidky(bnirlblwju) = dszwvakiaw xyeanovgmp (ynopxehhjr, 1/5 MTD) | - | 15 May 2015 | |||
Phase 1 | - | tbixascyzp(qdigblyvck) = thrombocytopenia and febrile neutropenia bhgcbtuqjm (psvnovzztg ) | - | 20 May 2011 | |||
Phase 1 | - | sewscjjoll(cbwxakkyua) = msudhhkwhv cwibwdwzpt (lmqstsfoci ) | - | 20 May 2010 | |||
Not Applicable | - | - | TLC388 Hydrochloride | yyckockijb(dtmgnrrgeq) = gdqdnnsttd tdoeuxtmqa (uljviihgjs ) View more | - | 01 Nov 2009 |